Comparison of nicardipine and propranolol for chronic stable angina pectoris

McGill, David; Mckenzie, W.; McCredie, Michael

doi:10.1016/0002-9149(86)90948-3

Cited by 19 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, differences in patient selection, study design, and drug dosages all prevent critical comparisons. Specific comparisons were β blockers and dihydropyridines,67 68 69 70 71 β blockers and diltiazem or verapamil,72 73 74 and studies with three drugs 75 76. Within the time frame of our search there was no compelling evidence to choose one β blocker over another (I) 77 78 79.…”

Section: Age Limitsmentioning

confidence: 99%

North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of stable angina

Eccles¹

1996

BMJ

View full text Add to dashboard Cite

Section: Age Limitsmentioning

confidence: 99%

North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of stable angina

Eccles¹

1996

BMJ

View full text Add to dashboard Cite

“…Nicardipine hydrochloride is a second-generation dihydropyridine calcium channel blocker with little effect on myocardial contractility or conduction (1,2) that has been shown to be effective for treating chronic stable angina (3)(4)(5)(6) in several short-term studies. Although previous studies (7,8) do suggest long-term efficacy of nicardipine for the reduction of anginal symptoms, the open-label design did not exclude spontaneous improvement of anginal symptoms or an exercise training effect in the change in symptoms or improvement on exercise parameters (9,10).…”

mentioning

confidence: 99%

Efficacy of Nicardipine for Long-Term Therapy of Chronic Stable Angina

Deedwania

Safford

Wood

et al. 1998

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

BACKGROUND: Although angina is a chronic disease, most clinical trials evaluating antianginal therapy are of a few weeks or months in duration. METHODS AND RESULTS: To evaluate the effects of nicardipine, a second-generation dihydro-pyridine calcium channel blocker, as long-term therapy, patients with chronic stable angina were treated for 1 year with open-label nicardipine. Anginal symptoms were controlled with 20 mg tid in 24%, 30 mg tid in 34%, and 40 mg tid in 42%. Of 72 patients completing the 1-year trial, only 14 (19%) had required the addition of long-acting nitrates for control of symptoms. The remaining 57 patients, who had anginal symptoms controlled with nicardipine alone, were continued into the 3-week, double-blind period and were randomized to continue their usual dose of nicardipine or placebo. Throughout the 1-year, open-label treatment period, the number of anginal episodes and exercise parameters of angina were significantly reduced with nicardipine. CONCLUSIONS: During the double-blind period, the patients who continued on nicardipine had significantly greater exercise time and time to onset of angina than patients who were randomized to placebo. The exercise parameters in the patients randomized to placebo were improved over baseline after 1 year of therapy; however, the improvement with nicardipine was significantly greater.

show abstract